NCT03217032 is a Phase 1 clinical trial of YUVA-GT-F801 in Hemophilia A, sponsored by Shenzhen Geno-Immune Medical Institute.

Who is sponsoring NCT03217032?

NCT03217032 is sponsored by Shenzhen Geno-Immune Medical Institute.

What drugs are being tested in NCT03217032?

Interventions in NCT03217032: YUVA-GT-F801.

What condition does NCT03217032 study?

NCT03217032 studies Hemophilia A.

Is NCT03217032 still recruiting?

NCT03217032 is currently status unknown. Last updated 23 May 2019.

Last reviewed 2019-05-23 · How we verify

NCT03217032

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lentiviral FVIII Gene Therapy

Status unknown Phase 1 Last updated 23 May 2019

What this trial tests

Phase 1 trial testing YUVA-GT-F801 in Hemophilia A in 10 participants. Status unknown.

Timeline

1 June 2020

Primary endpoint
31 May 2022

1 June 2022

Quick facts

Lead sponsor	Shenzhen Geno-Immune Medical Institute
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	1 June 2020
Primary completion	31 May 2022
Estimated completion	1 June 2022
Sites	1 location across China

Drugs / interventions tested

YUVA-GT-F801 — full drug profile →

Conditions studied

Hemophilia A — all drugs for Hemophilia A →

Sponsor

Shenzhen Geno-Immune Medical Institute

Who can join

Adults 2 to 65, any sex, with Hemophilia A. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a Phase I trial using an advanced lentiviral vector to deliver a functional gene for human clotting factor VIII into patients with hemophilia A, to evaluate the safety and efficacy of infusion of lentiviral gene modified autologous stem cells in patients.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Update on clinical gene therapy for hemophilia.
Perrin GQ, Herzog RW, Markusic DM. · · 2019 · cited 128× · PMID 30559260 · DOI 10.1182/blood-2018-07-820720
Novel vectors and approaches for gene therapy in liver diseases.
Maestro S, Weber ND, Zabaleta N, Aldabe R, et al · · 2021 · cited 81× · PMID 34159305 · DOI 10.1016/j.jhepr.2021.100300
A Molecular Revolution in the Treatment of Hemophilia.
Butterfield JSS, Hege KM, Herzog RW, Kaczmarek R. · · 2020 · cited 76× · PMID 31843450 · DOI 10.1016/j.ymthe.2019.11.006
Large-Scale Production of Lentiviral Vectors: Current Perspectives and Challenges.
Martínez-Molina E, Chocarro-Wrona C, Martínez-Moreno D, Marchal JA, et al · · 2020 · cited 55× · PMID 33153183 · DOI 10.3390/pharmaceutics12111051
Recent Advances in the Treatment of Hemophilia: A Review.
Marchesini E, Morfini M, Valentino L. · · 2021 · cited 53× · PMID 34163136 · DOI 10.2147/btt.s252580
Gene Therapy in Hemophilia: Recent Advances.
Rodríguez-Merchán EC, De Pablo-Moreno JA, Liras A. · · 2021 · cited 32× · PMID 34299267 · DOI 10.3390/ijms22147647
Haemophilia, state of the art and new therapeutic opportunities, a regulatory perspective.
Tomeo F, Mariz S, Brunetta AL, Stoyanova-Beninska V, et al · · 2021 · cited 23× · PMID 33772837 · DOI 10.1111/bcp.14838
An overview of development in gene therapeutics in China.
Wang D, Wang K, Cai Y. · · 2020 · cited 20× · PMID 32528163 · DOI 10.1038/s41434-020-0163-7

Verify or expand the search:

Other recruiting trials for Hemophilia A

Currently open trials in the same condition.

NCT07416526 — A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A · Phase 3 · recruiting
NCT07416604 — A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A · Phase 3 · recruiting
NCT07523399 — Joint Health, Balance and Quality of Life in Adults With Hemophilia A · recruiting
NCT06833983 — To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A · Phase 3 · recruiting
NCT06579144 — Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A · Phase 1 · recruiting

Other Shenzhen Geno-Immune Medical Institute trials

Trials by the same sponsor.

NCT07501156 — H3K27M-specific Immune Effector Cells Targeting DMG/DIPG · Phase 1, PHASE2 · recruiting
NCT07495956 — cfMSC Therapy for Diabetes · Phase 1, PHASE2 · recruiting
NCT07477600 — cfMSC Stem Cell Therapy Targeting COPD · Phase 1, PHASE2 · recruiting
NCT07180927 — DLL3 CAR-T Therapy Targeting Brain Tumors · Phase 1, PHASE2 · recruiting
NCT07193966 — NG2 and DLL3 CAR-T Cells Targeting Melanoma · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03217032 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shenzhen Geno-Immune Medical Institute
Last refreshed: 23 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03217032.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing